Loading organizations...
§ Private Profile · Dublin, Dublin, Ireland
Healthcare diagnostics company developing tests for osteoporosis risk and fragility fractures for individuals and providers.
Crescent Diagnostics is a healthcare organization headquartered in London, England, that develops specialized diagnostic tests to assess osteoporosis risk and predict potential fragility fractures for individuals and medical providers. The primary commercial offering of the enterprise is the BQT test, which analyzes fingernail or toenail clippings to evaluate overall bone health. Operating within the medical technology sector, the company has raised a total of two million two hundred thousand dollars in venture capital and grant funding to support its clinical diagnostics. This financial backing includes a Series A investment round of one and a half million euros provided by institutional investors such as the AIB Seed Capital Fund and Enterprise Ireland. Crescent Diagnostics was established in the year 2004 by undisclosed founders and currently operates under the strategic leadership of Chief Executive Officer Brendan Farrell.
Crescent Diagnostics has raised $2.1M across 1 funding round.
Crescent Diagnostics has raised $2.1M in total across 1 funding round.
Crescent Diagnostics has raised $2.1M across 1 funding round. Most recently, it raised $2.1M Series A in July 2011.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 18, 2011 | $2.1M Series A | — | Enterprise Equity, Kernel Capital, Seroba Life Sciences | Announced |
Crescent Diagnostics has raised $2.1M in total across 1 funding round.
Crescent Diagnostics's investors include Enterprise Equity, Kernel Capital, Seroba Life Sciences.